1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial

BACKGROUND: Imipenem/cilastatin/relebactam (IMI/REL) is approved for treating hospital-acquired/ventilator-associated bacterial pneumonia, complicated urinary tract infection, and complicated intra-abdominal infection in adults. This study assessed single-dose pharmacokinetics (PK), safety, and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, John S, Makieieva, Nataliia, Tøndel, Camilla, Roilides, Emmanuel, Kelly, Matthew S, Patel, Munjal, Vaddady, Pavan, Maniar, Alok, Zhang, Ying, Paschke, Amanda, Butterton, Joan R, Chen, Luke F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643896/
http://dx.doi.org/10.1093/ofid/ofab466.1352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643896/
http://dx.doi.org/10.1093/ofid/ofab466.1352

Ejemplares similares